Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 3/20 | 0.44 |
| ▸ | PTGES | O14684 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | CPA3 | P15088 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.40 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.39 |
| ▸ | LAP3 | P28838 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4547662 | 0.79 | POLB (0.31) | POLB | |
| SCHEMBL4547670 | 0.78 | POLB (0.33) | POLB | |
| SCHEMBL13629652 | 0.78 | CHRM1 (0.47) | PTGESALOX5PPARGCPA3CYP1A2 | |
| SCHEMBL1859177 | 0.74 | CYP1A2 (0.73) | ANPEPCPA3CYP1A2FOLH1ERAP2 | |
| SCHEMBL12035903 | 0.71 | FFAR4 (0.41) | POLB | |
| SCHEMBL10327379 | 0.70 | CPA3 (0.50) | ANPEPPPARGCPA3CYP1A2FOLH1 | |
| SCHEMBL4547668 | 0.69 | ALOX5 (0.40) | PTGESALOX5PPARGCYP1A2FOLH1 | |
| SCHEMBL1857365 | 0.68 | CYP1A2 (0.61) | ANPEPCPA3CYP1A2FOLH1ERAP2 | |
| SCHEMBL7439191 | 0.67 | GRIK1 (0.64) | ANPEPCPA3CYP1A2FOLH1ERAP2 | |
| SCHEMBL7439193 | 0.67 | GRIK1 (0.64) | ANPEPCPA3CYP1A2FOLH1ERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173704-B2 | Difluorophenol derivatives and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-08 | — | — | US | disclosed |
| US-20090291993-A1 | Difluorophenol Derivatives and Their Use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291993-A1 | Difluorophenol Derivatives and Their Use | TPMT, FABP3, DPP4 | ANPEP 1102/4885PTGES 1662/4885ALOX5 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.